Manage your stage 3 ET diagnosis with this guide on high-risk treatments, side effects and new NCCN-preferred options to empower your next visit. While essential thrombocythemia (ET) is classified as ...
The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy. A second phase 3 clinical trial has been ...
Essential thrombocythemia (ET) is a rare type of blood disorder in which a person’s bone marrow makes too many blood ...
MADRID and CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in ...
Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...
Results from a new clinical trial led by Wake Forest University School of Medicine and Atrium Health Levine Cancer shows a new therapy could provide significantly better outcomes for patients with ...
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs) RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...
Verywell Health on MSN
Should you be concerned about high platelets?
Medically reviewed by Gagandeep Brar, MD Key Takeaways A high platelet count can lead to blood clots and bleeding, which can be dangerous. Reactive thrombocytosis is often linked to another cause of ...
Verywell Health on MSN
JAK2 mutations and health impacts
Medically reviewed by Doru Paul, MD Key Takeaways A JAK2 mutation can make your body produce too many blood cells. JAK2 ...
Nearly all (90%) of essential thrombocythemia (ET) patients treated with INCA033989 at the higher dose achieved a hematologic response (HR) with 83.3% achieving a complete HR Molecular responses were ...
Bleeding in ET can range from minor mucocutaneous events to severe hemorrhages, with gastrointestinal bleeding being most common. The JAK2 V617F variant increases bleeding and thrombosis risk, ...
The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs) “The standard of care in essential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results